277 related articles for article (PubMed ID: 22901736)
1. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
7. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
Baldwin DS; Loft H; Florea I
Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
10. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
12. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Katona C; Hansen T; Olsen CK
Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C; Cutler AJ; She F; Eriksson H
Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
[TBL] [Abstract][Full Text] [Related]
16. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
17. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]